Global Dyslipidemia Drugs Market 2017-2021


◆タイトル:Global Dyslipidemia Drugs Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥486,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



ABSTRACTAbout Dyslipidemia Drugs

Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.

Technavio’s analysts forecast the global dyslipidemia drugs market to grow at a CAGR of 5.27% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global dyslipidemia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Dyslipidemia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca
• Merck
• Pfizer
• Sanofi

[Other prominent vendors]
• Alnylam Pharmaceuticals
• Amarin Corporation
• Amgen
• Bristol-Myers Squibb
• Catabasis Pharmaceuticals
• Cerenis
• Cipla
• CJ HealthCare
• CKD Bio
• Daewoong Pharmaceutical
• Daiichi Sankyo
• Eli Lilly
• Esperion Therapeutics
• GlaxoSmithKline
• JW Pharmaceuticals
• Kadmon Pharmaceuticals
• Lupin Pharmaceuticals

[Market driver]
• Change in ATP guidelines for management of hypercholesterolemia.
• For a full, detailed list, view our report

[Market challenge]
• Drawbacks associated with current therapies.
• For a full, detailed list, view our report

[Market trend]
• Increased uptake of OTC drugs.
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: An overview of dyslipidemia

PART 06: Pipeline analysis

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by drug class
• Statins
• Cholesterol absorption inhibitors
• Dyslipidemia injectables
• Others

PART 09: Geographical segmentation
• Dyslipidemia drugs market in Americas
• Dyslipidemia drugs market in EMEA
• Dyslipidemia drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments

PART 12: Market trends
• Increasing use of statins
• Combination therapies
• Increased uptake of OTC drugs

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• Aegerion Pharmaceuticals
• AstraZeneca
• Merck
• Pfizer
• Sanofi
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]

Exhibit 01: Key customer segments
Exhibit 02: Overview of phase III pipeline molecules in global dyslipidemia drugs market
Exhibit 03: Pipeline analysis
Exhibit 04: Global dyslipidemia drugs market snapshot 2016
Exhibit 05: Global dyslipidemia drugs market 2016-2021 ($ millions)
Exhibit 06: Five forces analysis
Exhibit 07: Global dyslipidemia drugs market by drug class
Exhibit 08: Global statin market 2016-2021 ($ millions)
Exhibit 09: Global cholesterol absorption inhibitors market 2016-2021 ($ millions)
Exhibit 10: Global dyslipidemia injectables market 2016-2021 ($ millions)
Exhibit 11: Global dyslipidemia drugs market by geography 2016 and 2021
Exhibit 12: Dyslipidemia drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 13: Market scenario in Americas
Exhibit 14: Dyslipidemia drugs market in Americas 2016-2021 ($ millions)
Exhibit 15: Market scenario in EMEA
Exhibit 16: Dyslipidemia drugs market in the EMEA 2016-2021 ($ millions)
Exhibit 17: Market scenario in APAC
Exhibit 18: Dyslipidemia drugs market in APAC 2016-2021 ($ millions)
Exhibit 19: Population aged 60 years and over: World and developed and developing regions (millions)
Exhibit 20: Impact of drivers
Exhibit 21: Impact of challenges
Exhibit 22: Competitive structure analysis of global dyslipidemia drugs market 2016
Exhibit 23: Competitive analysis of global dyslipidemia drugs market 2016
Exhibit 24: Market penetration of various players in global dyslipidemia drugs market 2016
Exhibit 25: Aegerion Pharmaceuticals: Key highlights
Exhibit 26: Aegerion Pharmaceuticals: Strength assessment
Exhibit 27: Aegerion Pharmaceuticals: Strategy assessment
Exhibit 28: Aegerion Pharmaceuticals: Opportunity assessment
Exhibit 29: AstraZeneca: Key highlights
Exhibit 30: AstraZeneca: Strength assessment
Exhibit 31: AstraZeneca: Strategy assessment
Exhibit 32: AstraZeneca: Opportunity assessment
Exhibit 33: Merck: Key highlights
Exhibit 34: Merck: Strength assessment
Exhibit 35: Merck: Strategy assessment
Exhibit 36: Merck: Opportunity assessment
Exhibit 37: Pfizer: Key highlights
Exhibit 38: Pfizer: Strength assessment
Exhibit 39: Pfizer: Strategy assessment
Exhibit 40: Pfizer: Opportunity assessment
Exhibit 41: Sanofi: Key highlights
Exhibit 42: Sanofi: Strength assessment
Exhibit 43: Sanofi: Strategy assessment
Exhibit 44: Sanofi: Opportunity assessment


AstraZeneca, Merck, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis, Cipla, CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, JW Pharmaceuticals, Kadmon Pharmaceuticals, and Lupin Pharmaceuticals.





★調査レポート[脂質異常症治療薬の世界市場2017-2021] (Global Dyslipidemia Drugs Market 2017-2021 / IRTNTR12273)販売に関する免責事項
[脂質異常症治療薬の世界市場2017-2021] (Global Dyslipidemia Drugs Market 2017-2021 / IRTNTR12273)についてEメールでお問い合わせ